3,360 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,360 shares of the biopharmaceutical company's stock, valued at approximately $3,532,000.

Other institutional investors also recently bought and sold shares of the company. Sachetta LLC grew its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 10 shares during the period. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $26,000. Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.2 %

Shares of REGN opened at $743.35 on Thursday. The company's 50-day simple moving average is $961.76 and its 200-day simple moving average is $1,030.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1 year low of $736.01 and a 1 year high of $1,211.20. The stock has a market capitalization of $81.69 billion, a PE ratio of 18.40, a P/E/G ratio of 2.81 and a beta of 0.15.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.48% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on REGN shares. Citigroup started coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a "neutral" rating and a $895.00 target price for the company. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a report on Friday, November 1st. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Finally, Wolfe Research began coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.